Prospective, Single Arm, Multi-centre, Observational Registry to Further Validate Safety and Efficacy of the Ultimaster Des System in Unselected Patients Representing Everyday Clinical Practice
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 11 Oct 2019
Price : $35 *
At a glance
- Drugs Sirolimus (Primary)
- Indications Coronary artery disease; Unstable angina pectoris
- Focus Therapeutic Use
- Acronyms e-Ultimaster
- Sponsors Terumo
- 06 Oct 2019 Planned End Date changed from 1 Sep 2019 to 1 Jun 2020.
- 06 Oct 2019 Planned primary completion date changed from 1 Jun 2019 to 1 Jun 2020.
- 17 May 2019 Planned primary completion date changed from 1 Sep 2018 to 1 Jun 2019.